This webinar, organized by the C-CB, addresses educational issues pertaining to natriuretic peptide (NP) assays and their role in laboratory medicine and clinical practice. Presentations addresses the differential diagnosis of increased NPs, review the appropriate indications for utilization of NPs for ruling in and ruling out heart failure and in assessing therapy and risk outcomes. Guideline and recommended medical decision thresholds will be addressed for appropriate NP assays use, along with educating audience on what BNP and NT-proBNP assays are measuring in health and disease.
Specifically, Drs Saenger and Kavsak will focus on the AACC and IFCC guidelines and recommendations pertaining to the analytical roles of the numerous BNP and NT-proBNP assays to better understand what forms of natriuretic peptides and their degradation products are being measured in acute and chronic heart failure patients. Further, they will address appropriate cutoff concentrations and how they should be determined for use in clinical practice. Prof. Lam with review how the similarities and potential differences for how BNP and NT-proBNP assays are used in clinical practice, along with international heart failure association practice guidelines and recommendations.
This webinar comprises of three following presentations of 20 min each, followed by 20 min of panel discussion at the end where the speakers will answer to your questions.
Chair/Moderator: Prof. Jordi Ordonez-Llanos
Talk 1: " Natriuretic Peptides: Laboratory & Assay Analytics Part 1" – Dr. Amy Saenger
Talk 2. " Natriuretic Peptides: Laboratory & Assay Analytics Part 2" – Dr. Peter Kavsak
Talk 3: " Clinical Utilization of Natriuretic Peptides in Heart Failure" - Prof. Carolyn S.P. Lam
This webinar, organized by the C-CB, addresses educational issues pertaining to high-sensitivity cardiac troponin I & T assays and their role in clinical practice. Evidence-based educational information addresses their utilization for the detection and management of myocardial injury, early rule out of myocardial infarction in the emergency department, and diagnostics and risk assessment and stratification in patients presenting with symptoms suggestive of ischemia. Current guidelines and recommendations are presented and appraised.
Specifically, Professor Jaffe elaborates on the non-ACS myocardial injury patients, Professor Omland on the role of hs-cTn assays in the diagnosis of type 1 and type 2 MIs as well as address baseline concentration pertaining to risk stratification and short and long term outcome assessment, while Professor Body focuses on both baseline and 0/1h and 0/2 h rule out pathways to better manage and triage patients presenting with symptoms suggestive of MI.
This webinar comprises of three following presentations of 20 min each, followed by 20 min of panel discussion at the end where the speakers will answer to your questions.
Chair/Moderator: Prof. Fred Apple
Talk 1: "Myocardial Injury" - Prof. Allan Jaffe
Talk 2. " Early Rule Protocols" - Prof. Richard Body
Talk 3: " Diagnosis and Risk Assessment" - Prof. Torbjørn Omland
This webinar, organized by the C-CB, addresses educational issues pertaining to high-sensitivity cardiac troponin I & T assays and the clinical laboratory’s role in patient care addressing assay imprecision, interferences and implementation, including point of care assays. We provides evidence-based information that laboratory professionals will be able to use to education their clinical colleagues for optimal interpretation of cTn measurements. Professor Apple will both moderate the session, as well as discuss the recent advances of whole blood POC hs-cTn assay. Professor Collinson will discuss the challenges related to real world practice in consideration of establishing hs-POC testing in parallel or combination with central laboratory testing. Dr. Aakre will address how imprecision of hs-cTn assays may affect patient classifications in early rule out strategies used in the emergency department. Professor Hammarsten will educate the audience on the latest developments of macro-troponin interferences that can be quite variable between hs-cTn assays, and explain how this interference concerns clinicians with interpretation during patient care.
This webinar comprises of three following presentations of 20 min each, followed by 20 min of panel discussion at the end where the speakers will answer to your questions.
Chair/Moderator: Prof. Fred Apple
Talk 1: "Challenges for Implementation" - Prof. Paul Collinson
Talk 2. " Analytical Performance of Assays and Effects on Algorithms Used in the Emergency Department" - Dr. Kristin Moberg Aakre
Talk 3: " Assay Interferences - Macro-Troponin" - Prof. Ola Hammarsten
Essentially all activities in the clinical laboratory carry with them the risk, some have greater potential for harm to patients and clients to various laboratory services. Maintaining a robust, safe, and high-quality laboratory service requires an acknowledgment of these risks and responding to this by embedding processes to measure and identify, analyze, and implement corrective actions to reduce frequency and impacts of risks, and/or provide warning systems to alert to situations where there is increased potential.
In this session, we provide an overview of risk management in healthcare focusing on clinical laboratories. We discuss the relationship of risk management to standards for best practice.
The presentations provide an explanation of explain how risk management is done and highlight risk management frameworks like Failure Modes and Effects Analysis (FMEA), Root Cause Analysis (RCA), and others. We finally explore how risk management strategies are used in continuous improvement initiatives, and other projects bringing about change to the laboratory work environment and its processes.
Name | Position | Country | Term | Time in Office |
F. Apple | Chair | US | 2nd | 2020 01 - 2022 12 |
P. Kavsak | Member | CA | 2nd | 2020 01 - 2022 12 |
O. Hammarsten | Member | SE | 1st | 2020 01 -2022 12 |
A. Saenger | Member | US | 2nd | 2020 01 - 2022 12 |
R. Body | Member | UK | 2nd | 2020 01 - 2022 12 |
N. Mills | Member | UK | 1st | 2022 03 - 2024 12 |
K. Moberg Aakre | Member | NO | 1st | 2021 01 - 2023 12 |
P. Collinson | Consultant | UK | ||
A. Jaffe | Consultant | US | ||
J. Ordoñez-Llanos | Consultant | ES | ||
T. Omland | Consultant | NO |
11 May 2022 On behalf of the members of the IFCC Committee on Clinical Applications of Cardiac Bio-Markers (C-CB), please find here below the updated set of tables. Please note that these tables represent information that were completed by the manufacturer. If after posting, the manufacturer notes any error, please email me ASAP, so these can be corrected. Also note that manufacturers may have submitted assays they claim to be ‘high sensitivity’ that do not meet the IFCC requirements of: a) ≤10% CV at the 99th percentile and b) ≥50% measurable concentrations ≥ LoD (Apple FS, Jaffe AS, Collinson P, Mockel M, Ordonez-Llanos J, Lindahl B, Hollander J, Plebani M, Than M, Chann MHM, on behalf of the IFCC Task Force on Clinical Applications of Cardiac Bio-Markers. IFCC educational materials on selected analytical and clinical applications of high-sensitivity cardiac troponin assays. Clin Biochem 2015: 2015;48:201-203). As a Committee we have not altered their information. I thank Amy Saenger PhD for her dedication to this project. Peace Fred Apple PhD, Chair IFCC C-CB Click on the titles to download the documents: |
Tables posted on 11 May 2022:
|
Name | Full and Affiliate Member Societies |
Caroline Le Goff | Royal Belgian Society of Laboratory Medicine (RBSLM) |
Galina Zemtsovskaja | Estonian Society of Laboratory Medicine |
Hannsjoerg Baum | Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V. (DGKL) |
Mamta Kantra | Association of Clinical Biochemists of India (ACBI) |
Monica Mion | Italian Society of Clinical Chemistry and Clinical Molecular Biology (SIBioC) |
Hiroshi Yoshida | Japan Society of Clinical Chemistry (JSCC) |
Dovile Karciauskaite | Lithuanian Society of Laboratory Medicine |
Steven Meex | Nederlandse Vereniging voor Klinische Chemie en Laboratoriumgeneeskunde (NVKC) |
Akinosun Bayo | Association of Clinical Chemists Nigeria (ACCN) |
Lakminda Thilakarathna | Association for Clinical Biochemistry, Sri Lanka |
Aylin Hakligor | Turkish Biochemical Society (TBS) |
Name | Corporate members |
Tricia Ravalico | ABBOTT Laboratories |
Adam Moss | ABBOTT APOC |
Lindsay Sun | BECKMAN COULTER |
Robert Zuk | ET HEALTHCARE |
Geert Jannes | FUJIREBIO Europe |
Yan Liu | MINDRAY |
Frank Ocklenburg | PHC Europe B.V. |
Jakob Eriksen | RADIOMETER |
Albert Gesa | ROCHE Diagnostics |
Kalen Nissen | SIEMENS Healthineers |
HuiJun Cui | SNIBE |
Corporate members | LEVEL SUPPORT |
ABBOTT | PLATINUM LEVEL SUPPORT |
ALERE | CRYSTAL LEVEL SUPPORT |
ET HEALTHCARE | BRONZE LEVEL SUPPORT |
ORTHO CLINICAL DIAGNOSTICS | GOLD LEVEL SUPPORT |
RADIOMETER | BRONZE LEVEL SUPPORT |
SIEMENS Healthineers | GOLD LEVEL SUPPORT |
BECKMAN COULTER | SILVER LEVEL SUPPORT |
ROCHE | SILVER LEVEL SUPPORT |
ChairProf. Fred APPLE |
Members | |
Dr Peter KAVSAK | Prof Ola HAMMARSTEN Professor and Senior Physician in Clinical Chemistry |
Dr Kristin Moberg Aakre | Dr Amy SAENGER |
Dr Richard BODY Emergency Medicine Research Office, Emergency Department, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, UK | Prof. Nick MILLS |
Consultants | |
Dr. Paul O. COLLISON | Dr. Allan JAFFE Cardiovascular Division, Gonda 5 Mayo Clinic 200 First Street SW Rochester - MN 55905 USA Tel.: +1 507 284 1648 |
Dr. Jordi ORDÓÑEZ-LLANOS | Dr Torbjørn OMLAND Akershus Universitetssykehus 1478 Lørenskog - NO |